Prof. Winblad offers more than 700 original publications in gerontology, geriatrics and dementia research. UBC held a meeting to discuss the Cognition Initiative, a multi-sponsor consortium to build up new measures befitting use as end factors in international cognition trials. This initiative brings together international professionals in cognition to develop new procedures to expand the number of outcomes assessed and to address the need for improved measurement sensitivity at gentle levels of impairment. Its main focus is the capture of the patient and caregiver perspective on relevant outcomes.. United BioSource Corporation announces during ICAD 2009 the addition of Professor Winblad to its European Scientific Advisory Plank for CNS Clinical Trials United BioSource Corporation announced this summer at ICAD 2009 that Bengt Winblad, MD, PhD has became a member of its European Scientific Advisory Table for CNS Clinical Trials.Cardiome signs commercialization contract with AOP for ESMOCARD products Cardiome Pharma Corp. Financial details of the agreement were not disclosed. ESMOCARD can be indicated for supraventricular tachycardia and for the quick control of the ventricular rate in individuals with atrial fibrillation or atrial flutter in perioperative, postoperative, or other situations where short-term control of the ventricular rate with a short-acting agent is desirable. ESMOCARD is also indicated for tachycardia and hypertension occurring in the perioperative phase and non-compensatory sinus tachycardia where, in the physician's judgement the fast heart rate requires particular intervention. ESMOCARD isn’t intended for use in chronic settings.